Sponsor
  • ·
  • Chinese Association of
    Integrative Medicine;
    China Academy of Chinese
    Medicine Sciences
Editing
  • ·
  • Editorial Board of
    China Journal of
    Orthopaedics and Traumatology
Publishing
  • ·
  • Publishing House,
    China Journal of
    Orthopaedics and Traumatology
Overseas Distributor
  • ·
  • China International Book
    Trading Corporation
    P.O.Box 399,Beijing,China
    Code No.M587
Mail-order
  • ·
  • Publishing House,
    China Journal of
    Orthopaedics and Traumatology
    No.16A, Nanxiaojie, Dongzhimennei,
    Beijing 100700,China
    Tel:0086-10-84020925
    Fax:0086-10-84036581
    Http://www.zggszz.com
    E-mail:zggszz@sina.com
绝经后骨质疏松症合并血脂异常患者临床特征及影响因素分析
Hits: 135   Download times: 13   Received:March 13, 2025    
作者Author单位UnitE-Mail
谢榕 XIE Rong 北京中医药大学, 北京 100029
中国中医科学院望京医院, 北京 100102
Beijing University of Chinese Medicine, Beijing 100029, China
Wangjing Hospital, China Academy of Traditional Chinese Medicine, Beijing 100102, China
 
朱立国 ZHU Li-guo 中国中医科学院望京医院, 北京 100102 Wangjing Hospital, China Academy of Traditional Chinese Medicine, Beijing 100102, China  
金子开 JIN Zi-kai 北京中医药大学, 北京 100029 Beijing University of Chinese Medicine, Beijing 100029, China  
冯天笑 FENG Tian-xiao 北京中医药大学, 北京 100029 Beijing University of Chinese Medicine, Beijing 100029, China  
赵柯 ZHAO Ke 中国中医科学院望京医院, 北京 100102 Wangjing Hospital, China Academy of Traditional Chinese Medicine, Beijing 100102, China  
王达 WANG Da 中国中医科学院望京医院, 北京 100102 Wangjing Hospital, China Academy of Traditional Chinese Medicine, Beijing 100102, China  
李玲慧 LI Ling-hui 中国中医科学院望京医院, 北京 100102 Wangjing Hospital, China Academy of Traditional Chinese Medicine, Beijing 100102, China  
魏戌 WEI Xu 中国中医科学院望京医院, 北京 100102 Wangjing Hospital, China Academy of Traditional Chinese Medicine, Beijing 100102, China weixu.007@163.com 
期刊信息:《中国骨伤》2025年25卷,第5期,第487-493页
DOI:10.12200/j.issn.1003-0034.20250217
基金项目:中国中医药循证医学中心"业务研究室主任专项"(编号.2020YJSZX-4);中国中医科学院卓越青年科技人才培养专项(编号.CI2024D003)


目的:探讨绝经后骨质疏松症(postmenopausal osteoporosis,PMOP)与血脂异常的共病影响因素,为临床共病管理提供循证依据。

方法:基于2017年至2018年北京市社区横断面调查数据,纳入PMOP患者,根据是否并发血脂异常分为血脂异常组与未合并血脂异常组。通过问卷采集人口学特征、生活习惯及疾病史,现场检测骨密度及骨代谢生物标志物(骨钙素、血钙、血清Ⅰ型胶原氨基端前肽等)。采用二元Logistic回归分析共病危险因素。

结果:纳入320例PMOP患者,其中并发组75例,未并发组245例。结果显示心血管疾病史[OR=1.801,95%CI(1.003,3.236),P=0.049]、脑血管疾病史[OR=2.923,95%CI(1.460,5.854),P=0.002]、煎炸烹调方式[OR=5.388,95%CI(1.632,17.793),P=0.006]、骨钙素(osteocalcin,OST)结果[OR=0.910,95%CI(0.843,0.983),P=0.016]、血Ca结果[OR=60.249,95%CI(1.862,1 949.926),P=0.021]可能是PMOP并发血脂异常的影响因素。

结论:应重点关注PMOP和血脂异常共病的影响因素,重视多维度评估,结合生活方式干预与骨代谢标志物监测以优化共病管理。
[关键词]:绝经后骨质疏松症  血脂异常  共病  影响因素
 
Analysis of clinical characteristics and influencing factors of patients with postmenopausal osteoporosis combined with dyslipidemia
Abstract:

Objective To explore the co-morbid influencing factors of postmenopausal osteoporosis(PMOP) and dyslipidemia,and to provide evidence-based basis for clinical co-morbidity management.

Methods Based on the 2017 to 2018 Beijing community cross-sectional survey data,PMOP patients were included and divided into the dyslipidemia group and the uncomplicated dyslipidemia group according to whether they were comorbid with dyslipidemia. Demographic characteristics,living habits and disease history were collected through questionnaires,and bone mineral density and bone metabolism biomarkers (osteocalcin,blood calcium,serum typeⅠprocollagen N-terminal prepeptide,etc.) were detected on site. Co-morbidity risk factors were analyzed using binary logistic regression. Results Three hundred and twenty patients with PMOP were included,including the comorbid group (75 patients) and the uncomplicated group (245 patients). The Results showed that history of cardiovascular disease[OR=1.801,95%CI(1.003,3.236),P=0.049],history of cerebrovascular disease[OR=2.923,95%CI(1.460,5.854),P=0.002],frying and cooking methods[OR=5.388,95%CI(1.632,17.793),P=0.006],OST results[OR=0.910,95%CI(0.843,0.983),P=0.016],and blood Ca results[OR=60.249,95%CI(1.862,1 949.926),P=0.021] were the influencing factors of PMOP complicated with dyslipidemia.

Conclusion Focus should be placed on the influencing factors of PMOP and dyslipidemia co-morbidities,with emphasis on multidimensional assessment,combining lifestyle interventions with bone metabolism marker monitoring to optimize co-morbidity management.
KEYWORDS:Postmenopausal osteoporosis  Dyslipidemia  Co-morbidities  Influencing factors
 
引用本文,请按以下格式著录参考文献:
中文格式:谢榕,朱立国,金子开,冯天笑,赵柯,王达,李玲慧,魏戌.绝经后骨质疏松症合并血脂异常患者临床特征及影响因素分析[J].中国骨伤,2025,25(5):487~493
英文格式:XIE Rong,ZHU Li-guo,JIN Zi-kai,FENG Tian-xiao,ZHAO Ke,WANG Da,LI Ling-hui,WEI Xu.Analysis of clinical characteristics and influencing factors of patients with postmenopausal osteoporosis combined with dyslipidemia[J].zhongguo gu shang / China J Orthop Trauma ,2025,25(5):487~493
View Full Text  View/Add Comment  Download reader
Close




版权所有:Editorial Office of China Journal of Orthopaedics and Traumatology京ICP备12048066号  版权声明
地址:No.16A, Nanxiaojie, Dongzhimennei, Beijing 100700, China
电话:0086-10-84036581 传真:0086-10-84036581 Email:zggszz@sina.com